Ensysce Biosciences Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

ENSC$0.36+10.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Federal grants	$181,797	$490,472	$487,519	$1,280,107
Operating expenses:
Research and development	947,229	1,643,726	1,726,133	3,439,742
General and administrative	1,190,010	1,140,700	2,559,791	2,695,553
Total operating expenses	2,137,239	2,784,426	4,285,924	6,135,295
Loss from operations	(1,955,442)	(2,293,954)	(3,798,405)	(4,855,188)
Other income (expense):
Change in fair value of convertible notes	-	-	-	146,479
Change in fair value of liability classified warrants	7,818	43,622	16,773	262,650
Interest expense, net	(27,563)	-	(1,275,628)	(1,497)
Other income, net	7,394	11,030	(27,096)	16,448
Total other income (expense), net	(12,351)	54,652	(1,285,951)	424,080
Net loss	$(1,967,793)	$(2,239,302)	$(5,084,356)	$(4,431,108)
Net loss attributable to noncontrolling interests	-	(7,060)	(74)	(11,001)
Deemed dividend related to warrants down round provision	-	3,729	290	12,038
Net loss attributable to common stockholders	$(1,967,793)	$(2,235,971)	$(5,084,572)	$(4,432,145)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic and diluted	$(0.22)	$(0.98)	$(0.67)	$(2.66)
Weighted average common shares outstanding, basic and diluted	8,817,316	2,274,113	7,640,192	1,667,527

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.